AlphaValue Corporate Services
COVERAGE ABOUT US CONTACT FR
This research has been commissioned and paid for by the company and does therefore not constitute an inducement caught by the prohibition under MiFID II

Crossject

CR 		Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things are getting going...hopefully
Target
Upside 217%
Price (€) 2.40
Target Price (€) 7.60
Market Cap (€M) 98.9
Perf. 1W: 4.13%
Perf. 1M: 10.9%
Perf. 3M: 26.2%
Perf Ytd: -51.3%
10 day relative perf. to stoxx600: 0.95%
20 day relative perf. to stoxx600: 3.42%
EPS change05/09/2022 07:56
Download

Adjusting our forecasts to the new number of shares
Change in EPS2022 : € -0.23 vs -0.26ns
2023 : € -0.25 vs -0.31ns

We have adjusted our numbers to the current number of shares (after the latest exercise of subscription rights) which now stands at 34.83m as of August 2022. As a result, the loss per share for FY22/23 decreases.
Change in NAV€ 12.3 vs 13.3-7.88%

We have adjusted our numbers to the current number of shares (after the exercise of subscription rights) which now stands at 34.83m as of August 2022.
Change in DCF€ 13.3 vs 14.6-9.05%

We have adjusted our numbers to the current number of shares (after the latest exercise of subscription rights) which now stands at 34.83m as of August 2022.
.